Patrick C. Johnson, Md

This study tests whether combining the drug acalabrutinib with a cell therapy called liso-cel can shrink or eliminate aggressive B-cell lymphomas that have returned or not responded to prior treatments. About 28 adults with these hard-to-treat cancers will receive the combination…